Trials / Completed
CompletedNCT00694356
Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)
A Phase I Study of MK-0646 in Patients With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This clinical study evaluates the safety, tolerability, pharmacokinetics, and immunogenicity of dalotuzumab (MK-0646) in participants with relapsed or refractory locally advanced or metastatic solid tumors using once weekly and once every other week dose infusion regimens. The primary study hypothesis is that administration of dalotuzumab as a once weekly and an every other week infusion will be generally safe and well tolerated
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Dalotuzumab | IV infusion |
Timeline
- Start date
- 2008-08-04
- Primary completion
- 2009-03-18
- Completion
- 2009-04-28
- First posted
- 2008-06-10
- Last updated
- 2018-08-08
- Results posted
- 2017-06-15
Source: ClinicalTrials.gov record NCT00694356. Inclusion in this directory is not an endorsement.